|
|
Dr Damian O'Connell
Executive Director Clinical R&D
Pfizer Global R&D
Dr David Jones
Principal Scientific Officer
MHRA
Prof Robert Lechler
Chairman, Expert Advisory Group on Novel Biological Agents
Committee for Safety of Medicine
Dr Joel Scherer
Managing Director of Chorus
Eli Lilly
Dr Jackie Hunter
Senior Vice President, Science Environment Development
GlaxoSmithKline
|
Conference:
Pre conference workshop
12 May 9.30am - 4:30pm
Day 1
13 May 8.30am - 7:30pm
Day 2
14 May 7.30am - 5:30pm
Post conference workshop
15 May 9.30am - 4:30pm
Venue: Olympia Conference Centre, London, United Kingdom
› About the conference
› Add this to my calendar
|
|
|
|
The 3rd annual conference
The 3rd annual Exploratory Clinical Development World Europe will build on last year’s success and provide participants with a comprehensive review of possible solutions to managing the challenges in early clinical development.
Confirmed speakers to date:
- Dr Valerie Kitchens, Vice President, ID MDC, GlaxoSmithKline
- Dr Thomas Senderovitz, Vice President Global Clinical Development, UCB, R&D
- Prof Johan Luthman, Head Exploratory Medicine Neurology, PoC Management & Liaison, Merck Serono International S.A.
- Dr Heinz Schmidli, Senior Expert Statistician, Pharma Clinical Development, Novartis
- Dr Patricia Cole, Senior Director, Global Head, Imaging Biomarkers, Eisai Medical Research, Inc.
Dr Mike Hale, Heads of Global Medical Sciences Biostatistics group, Amgen
- Dr Piet van der Graaf, Research Fellow, Preclinical Modelling & Simulation, Pfizer Global Research & Development
- Dr Jackie Hunter, Senior Vice President and Head of Neurology and Gastrointestinal CEDD, GlaxoSmithKline
- Dr Marc Pfister, Executive Director, Discovery Medicine and Clinical Pharmacology, Head of Strategic Modelling and Simulation, Research & Development, Bristol Myers Squibb Co.
- Dr Mohammad Tabrizi, Director, Translational Sciences, Global PK-PD & Bioanalysis, MedImmune
- Dr Kamilla Buchberg Petersen, Specialist, Clinical Pharmacology & Pharmacokinetics, Lundbeck
- Dr Walter Janssens, Senior Assessor Preclinical, Department Research & Development, Federal Agency for Medicinal and Health Products
- Dr Håkan Wennbo, Global Project Director, Cardiovascular & Gastrointestinal, AstraZeneca
- Dr David Jones, Principal Scientific Officer, Medicines and Healthcare Products Agency
- Prof Dr Jan de Hoon, Head of Department, Centre for Clinical Pharmacology, University of Leuven
- Dr Damian O’Connell, Executive Director, Clinical R&D, Pfizer Global Research and Development
- Dr Ansar Jawaid, Global Group Leader, R&D genetics and Personalised medicine, AstraZeneca
- Prof Krishna Prasad, Clinical Medical Assessor, MHRA
- Dr John Lyons, VP Translational Research, Astex Therapeutics
- Dr Don Nichols, Executive Director, Head of Clinical Pharmacology, Pain Therapeutic Area, Pfizer
- Dr Richard J. Weaver, Head of Metabolism & Pharmacokinetics, Centre for Biopharmacy Research, Servier Research & Development Ltd
- Dr Michael-Friedrich Boettcher, Global Clinical Pharmacological Project Leader, Bayer Healthcare
- Dr William B. Mattes, Director of Toxicology, The Critical Path Institute
- Dr Gilles Hanton, Senior Director Preclinical Toxicology, Tibotec
- Dr Kevin Johnson, Chief Executive Officer, PanGenetics BV
- Dr. Gerd Maass, President & CEO, Roche NimbleGen, Inc
- Dr Christian Steffen, Medical Assessor, BfArM
- Rachael Grose-Hodge, Senior Clinical Scientist, Shire
- Dr Joel Scherer, Managing Director of Chorus, Eli Lilly
For information about speaking opportunities, please fill in the form in the link below and a member of the team will call you.
» Speaking opportunities
Conference at a glance
The conference programme has been developed using delegate feedback and extensive industry research with senior members working in exploratory development. Below are the core topics that we will be presented at Exploratory Clinical Development World, Europe:
*Innovative management strategies to revolutionize research and development
*Role of experimental medicine in exploratory development
*Role of Innovative Medicines Initiative and Critical Path Initiative in helping to over come bottlenecks
*Managing the transition between preclinical and first in man studies
*Advancing proof of concept tools and approaches
*Outsourcing in phase I
*Managing risk in early development
*Study design and dosing strategies
*Regulatory status and review
*Evaluation of biomarkers in early development
*Cardiac safety study design and strategies
*Translation PK/PD
*Modelling and simulation
Request a full agenda
|
|
|
|
|
|
